Association of Lung Microbiota With Intensive Care Unit Mortality in ARDS Patients: MicrA Study
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- lung bacteriobiota and ICU mortality
研究概览
简要总结
Acute respiratory distress syndrome (ARDS) is due to diffuse and severe lung inflammation. Despite intensive research, few therapeutics have emerged and treatment is still mostly symptomatic. As lung microbiota seems to be associated with lung inflammation in numerous chronic respiratory diseases, this study aims to analyse the correlation between lung microbiota and mortality.
详细描述
ARDS is caused by diffuse intense lun inflammation. Its mortality rate is still about 40%. Despite decades of research, few therapeutics have emerged. Treatment is based on the treatment of ARDS cause, if possible and on protective ventilation, curare use and prone position. For more severe cases, nitric monoxide inhalation and extra-corporeal membrane oxygenation can be considered. Nevertheless, no treatment specifically addresses lung inflammation. Lung microbiota has been shown to be associated with lung inflammation in asthma, chronic obstructive disease and cystic fibrosis. Lung microbiota also plays a role in lung immunity. Regarding specifically ARDS, one study correlated lung microbiota with the occurrence of non-infectious ARDS in trauma patients. Thi study therefore aims to analyse the correlation between lung microbiota at admission to ICU for ARDS with mortality.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient above 18 year-old admitted to intensive care unit
- •ARDS according to Berlin criteria
- •Needing oro-tracheal intubation for mechanical ventilation
- •Within the first 48 hours of ARDS evolution
排除标准
- •Guardianship or curatorship
- •Prisoners
- •No health insurance
- •No legal representative
结局指标
主要结局
lung bacteriobiota and ICU mortality
时间窗: at admission
Comparison of lung bacteriobiota alpha diversity between ARDS ICU survivors and non-survivors
次要结局
- fungi and 1-month mortality(microbiota : at admission, mortality: 1 month after inclusion)
- bacteria and ICU mortality(at admission)
- lung bacteriobiota and ICU mortality(at admission)
- bacteria and 1-month mortality(microbiota : at admission, mortality: 1 month after inclusion)
- lung mycobiota and ICU mortality(at admission)
- lung mycobiota and 1-month mortality(microbiota : at admission, mortality: 1 month after inclusion)
- lung bacteriobiota and 1-month mortality(microbiota : at admission, mortality: 1 month after inclusion)
- fungi and ICU mortality(at admission)
研究者
Dr Pauline Esteves
Doctor
University of Bordeaux